<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548066" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548066/" /><meta name="ncbi_pagename" content="Ciprofloxacin - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Ciprofloxacin - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Ciprofloxacin" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/02/28" /><meta name="citation_pmid" content="31643397" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548066/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Ciprofloxacin" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/02/28" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548066/" /><meta name="description" content="Ciprofloxacin is a second generation fluoroquinolone antibiotic that is widely used in the therapy of mild-to-moderate urinary and respiratory tract infections caused by susceptible organisms. Ciprofloxacin has been linked to rare but convincing instances of liver injury that can be severe and even fatal." /><meta name="og:title" content="Ciprofloxacin" /><meta name="og:type" content="book" /><meta name="og:description" content="Ciprofloxacin is a second generation fluoroquinolone antibiotic that is widely used in the therapy of mild-to-moderate urinary and respiratory tract infections caused by susceptible organisms. Ciprofloxacin has been linked to rare but convincing instances of liver injury that can be severe and even fatal." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548066/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Ciprofloxacin/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548066/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D161D04663E5100000000058F01A1.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548066_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548066_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Cimetidine/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Cisplatin/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548066_"><span class="title" itemprop="name">Ciprofloxacin</span></h1><p class="small">Last Update: <span itemprop="dateModified">February 28, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Ciprofloxacin.OVERVIEW"><h2 id="_Ciprofloxacin_OVERVIEW_">OVERVIEW</h2><div id="Ciprofloxacin.Introduction"><h3>Introduction</h3><p>Ciprofloxacin is a second generation fluoroquinolone antibiotic that is widely used in the therapy of mild-to-moderate urinary and respiratory tract infections caused by susceptible organisms. Ciprofloxacin has been linked to rare but convincing instances of liver injury that can be severe and even fatal.</p></div><div id="Ciprofloxacin.Background"><h3>Background</h3><p>Ciprofloxacin (sip" roe flox' a sin) is an oral fluoroquinolone that is used to treat mild-to-moderate urinary and respiratory tract infections. Ciprofloxacin is also used for infectious diarrhea, typhoid fever, uncomplicated gonorrhea, treatment of Neisseria meningitides nasal carriage and prophylaxis against anthrax. Like other fluoroquinolones, ciprofloxacin is active against a wide range of aerobic gram-positive and gram-negative organisms. The fluoroquinolones are believed to act by inhibition of bacterial DNA gyrase and topoisomerase IV that are required for synthesis of bacterial mRNAs (transcription) and DNA replication. In contrast, DNA gyrases are not present in human [and other eukarotic] cells and the equivalent topoisomerases are not sensitive to fluoroquinolone inhibition. Ciprofloxacin was approved for use in the United States in 1990 and, currently, approximately 7 million prescriptions are filled yearly. Ciprofloxacin is available in multiple oral formulations of 100, 250, 500 and 750 mg tablets and extended release formulations of 500 and 1000 mg tablets. Ciprofloxacin is available generically and under several commercial names including Cipro and Proquin. The usual oral dose is 250 to 500 mg every 12 hours. Oral formulations are recommended for mild-to-moderate infections due to susceptible organisms, including urinary tract infections, sinusitis, bronchitis, skin infections, urethral and cervical infections. Intravenous formulations are available for moderate to severe infections, including pneumonia, sinusitis, septicemia, intraabdominal and bone and joint infections, the usual dosages being 200 to 400 mg intravenously every 8 hours. Oral therapy is typically continued for 7 to 10 days, but both shorter and longer courses are used. Common side effects include gastrointestinal upset, headaches, skin rash and allergic reactions. Less common, but more severe side effects include prolongation of the QT interval, seizures, hallucinations, tendon rupture, angioedema, Stevens Johnson syndrome and photosensitivity.</p></div><div id="Ciprofloxacin.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Ciprofloxacin like other fluoroquinolones is associated with a low rate (1% to 3%) of serum enzyme elevations during therapy. These abnormalities are generally mild, asymptomatic and transient, resolving even with continuation of therapy. More importantly, ciprofloxacin has been linked to rare, but occasionally severe and even fatal cases of acute liver injury. The time to onset is typically short (2 days to 2 weeks) and the presentation is often abrupt with nausea, fatigue and abdominal pain, followed by dark urine and jaundice. The pattern of serum enzyme elevations can be either hepatocellular or cholestatic; cases with the shorter times to onset usually being more hepatocellular with markedly elevated <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> levels, and occasionally with rapid worsening of prothrombin time and early signs of hepatic failure. The onset of illness also may occur a few days after the medication is stopped. Cases with a cholestatic pattern of enzymes may run a prolonged course, but are usually self-limiting. Nevertheless, chronic cholestasis and vanishing bile duct syndrome have been reported with ciprofloxacin and other fluoroquinolones. Finally, the enzyme pattern can be initially hepatocellular and then evolve during the course of illness from a hepatocellular into a mixed or cholestatic pattern. Many (but not all) cases have had allergic manifestations with fever, rash and eosinophilia. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.autoantibodies/">Autoantibodies</a> are usually not present.</p><p>Likelihood score: B (likely cause of clinically apparent liver injury).</p></div><div id="Ciprofloxacin.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism of ciprofloxacin hepatotoxicity is suspected to be hypersensitivity. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.rechallenge/">Rechallenge</a> leads to recurrence with a shorter time to onset and more severe course and should be avoided.</p></div><div id="Ciprofloxacin.Outcome_and_Management"><h3>Outcome and Management</h3><p>Severity ranges from mild and transient serum enzyme elevations to a self-limited hepatitis, to prolonged cholestatic hepatitis to a fulminant hepatic failure. If not fatal during the acute phase, complete recovery is expected after stopping the drug and is usually rapid (2 to 4 weeks) depending upon the severity and degree of cholestasis. Some instances of cholestatic liver injury from ciprofloxacin have resulted in vanishing bile duct syndrome. Corticosteroids have been used with variable degrees of success. Cross reactivity of the hepatic injury between different fluoroquinolones has been demonstrated in a small number of cases, but should be assumed based upon the similarity of clinical patterns of injury and latency. Thus, patients should be advised to avoid further exposure to the fluoroquinolones.</p><p>Drug Class: <a href="/books/n/livertox/Antiinfective/">Antiinfective Agents</a></p><p>Other Drugs in the Subclass, <a href="/books/n/livertox/Fluoroquinolones/">Fluoroquinolones</a>: <a href="/books/n/livertox/Delafloxacin/">Delafloxacin</a>, <a href="/books/n/livertox/Gemifloxacin/">Gemifloxacin</a>, <a href="/books/n/livertox/Levofloxacin/">Levofloxacin</a>, <a href="/books/n/livertox/Moxifloxacin/">Moxifloxacin</a>, <a href="/books/n/livertox/Norfloxacin/">Norfloxacin</a>, <a href="/books/n/livertox/Ofloxacin/">Ofloxacin</a></p></div></div><div id="Ciprofloxacin.CASE_REPORTS"><h2 id="_Ciprofloxacin_CASE_REPORTS_">CASE REPORTS</h2><div id="Ciprofloxacin.Case_1_Cholestatic_hepatit"><h3>Case 1. Cholestatic hepatitis due to ciprofloxacin therapy.(<a class="bk_pop" href="#Ciprofloxacin.REF.1">1</a>)</h3><p>An 84 year old female resident of a long term care facility received a course of ciprofloxacin for urinary tract infection. Six days later she was found to have a rash and ciprofloxacin was stopped. Nevertheless, 3 days after stopping she was noted to be jaundiced. Serum bilirubin rose to as high as 8.2 mg/dL, but she recovered within 6 weeks.</p><div id="Ciprofloxacin.Key_Points"><h4>Key Points</h4><div id="Ciprofloxacin.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548066/table/Ciprofloxacin.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Ciprofloxacin.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_Ciprofloxacin.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Ciprofloxacin.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ciprofloxacin, 500 mg daily for 6 days</td></tr><tr><th id="hd_b_Ciprofloxacin.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Ciprofloxacin.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cholestatic (R=0.2)</td></tr><tr><th id="hd_b_Ciprofloxacin.Tc_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Ciprofloxacin.Tc_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3+ (jaundice and hospitalization)</td></tr><tr><th id="hd_b_Ciprofloxacin.Tc_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Ciprofloxacin.Tc_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 days</td></tr><tr><th id="hd_b_Ciprofloxacin.Tc_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Ciprofloxacin.Tc_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Approximately 6 weeks</td></tr><tr><th id="hd_b_Ciprofloxacin.Tc_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Ciprofloxacin.Tc_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cefoperazone IV for 6 days before starting ciprofloxacin; and docusate/casanthranol, lorazepam and acetaminophen chronically as needed.</td></tr></tbody></table></div></div></div><div id="Ciprofloxacin.Laboratory_Values"><h4>Laboratory Values</h4><div id="Ciprofloxacin.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548066/table/Ciprofloxacin.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Ciprofloxacin.Td_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_Ciprofloxacin.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Starting</th><th id="hd_h_Ciprofloxacin.Td_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Stopping</th><th id="hd_h_Ciprofloxacin.Td_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a><br />(U/L)</th><th id="hd_h_Ciprofloxacin.Td_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P<br />(U/L)</th><th id="hd_h_Ciprofloxacin.Td_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a>*<br />(mg/dL)</th><th id="hd_h_Ciprofloxacin.Td_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Ciprofloxacin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">20</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">158</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.5</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Ciprofloxacin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 days</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_3 hd_h_Ciprofloxacin.Td_1_1_1_4 hd_h_Ciprofloxacin.Td_1_1_1_5 hd_h_Ciprofloxacin.Td_1_1_1_6" colspan="4" rowspan="1" style="text-align:center;vertical-align:top;">Ciprofloxacin stopped because of rash</td></tr><tr><td headers="hd_h_Ciprofloxacin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9 days</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 days</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">64</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1119</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7.8</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">No eosinophilia</td></tr><tr><td headers="hd_h_Ciprofloxacin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 days</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 days</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">126</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1411</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">8.2</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Abdominal ultrasound normal</td></tr><tr><td headers="hd_h_Ciprofloxacin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 weeks</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 weeks</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">60</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">866</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.7</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Ciprofloxacin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 weeks</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 weeks</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">15</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">317</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.5</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Ciprofloxacin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 weeks</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 weeks</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">23</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">201</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.0</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Ciprofloxacin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.5 months</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">115</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.6</td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Ciprofloxacin.Td_1_1_1_1 hd_h_Ciprofloxacin.Td_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;41</b></td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;115</b></td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Ciprofloxacin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>* </dt><dd><div id="Ciprofloxacin.TF.d.1"><p class="no_margin">Converted from &#x000b5;mol/L.</p></div></dd></dl></div></div></div></div><div id="Ciprofloxacin.Comment"><h4>Comment</h4><p>This patient received multiple medications, but the timing of onset and pattern of injury was typical of fluoroquinolone induced liver injury with short latency and rapid recovery upon withdrawal. The cholestatic pattern of injury is somewhat atypical, but occurs when the jaundice is severe and prolonged; also, the lack of blood tests at earlier time points precludes a full assessment of the enzyme response. Interestingly, this patient had received two previous courses of ciprofloxacin and was said to be allergic to sulfonamides.</p></div></div><div id="Ciprofloxacin.Case_2_Severe_acute_hepati"><h3>Case 2. Severe acute hepatitis due to ciprofloxacin therapy.(<a class="bk_pop" href="#Ciprofloxacin.REF.2">2</a>)</h3><p>An 80 year old female developed nausea, anorexia and increasing forgetfulness followed by jaundice starting the week after completing a 10 day course of ciprofloxacin (500 mg twice daily) and while taking metronidazole (250 mg twice daily). She had a past medical history of hypertension, congestive heart failure, atrial fibrillation, colonic polyps and depression. Her other medications included furosemide, atenolol, valsartan, warfarin, vitamins and ginkgo biloba. She also took occasional acetaminophen with or without oxycodone for pain. She had no history of liver disease or risk factors for viral hepatitis and did not drink alcohol. Two months before onset of jaundice, she had developed diarrhea and abdominal pain which was presumed to be diverticulitis and for which she was given the two antibiotics. During the week before admission, she had increasing fatigue and forgetfulness and the day before presentation developed pruritus, dark urine and jaundice. Physical examination was unremarkable except for jaundice. She did not have fever, rash, hepatomegaly, splenomegaly, ascites or asterixis. Laboratory testing showed total bilirubin of 9.6 mg/dL (direct 6.8 mg/dL), <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> 705 U/L and INR 8.2 (Table). There was mild eosinophilia. Serum antinuclear antibody was negative, smooth muscle antibody was weakly positive (1:20). She was admitted and all medications including warfarin were stopped. Because of concern over acute liver failure, she was transferred to a tertiary care hospital for management. Tests for hepatitis A, B and C (including HCV RNA) were negative as were tests for Epstein Barr virus and cytomegalovirus infection. CT scans showed mild hepatosplenomegaly, mild ascites, absence of a gall bladder and no evidence of biliary obstruction. A liver biopsy showed severe acute hepatitis with giant cells and bridging necrosis. She developed worsening jaundice, ascites, and hepatic encephalopathy and died of multiorgan failure 5 weeks after onset of jaundice.</p><div id="Ciprofloxacin.Key_Points_1"><h4>Key Points</h4><div id="Ciprofloxacin.Te" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548066/table/Ciprofloxacin.Te/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Ciprofloxacin.Te_lrgtbl__"><table><tbody><tr><th id="hd_b_Ciprofloxacin.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Ciprofloxacin.Te_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ciprofloxacin, 500 mg daily for 10 days</td></tr><tr><th id="hd_b_Ciprofloxacin.Te_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Ciprofloxacin.Te_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hepatocellular (R=11.1)</td></tr><tr><th id="hd_b_Ciprofloxacin.Te_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Ciprofloxacin.Te_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5+ (death from acute liver failure)</td></tr><tr><th id="hd_b_Ciprofloxacin.Te_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Ciprofloxacin.Te_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18 days (5 days after stopping medication)</td></tr><tr><th id="hd_b_Ciprofloxacin.Te_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Ciprofloxacin.Te_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr><tr><th id="hd_b_Ciprofloxacin.Te_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Ciprofloxacin.Te_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Metronidazole for previous 18 days; warfarin, atenolol, valsartan, furosemide chronically</td></tr></tbody></table></div></div></div><div id="Ciprofloxacin.Laboratory_Values_1"><h4>Laboratory Values</h4><div id="Ciprofloxacin.Tf" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548066/table/Ciprofloxacin.Tf/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Ciprofloxacin.Tf_lrgtbl__"><table><thead><tr><th id="hd_h_Ciprofloxacin.Tf_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Days After<br />Starting</th><th id="hd_h_Ciprofloxacin.Tf_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Days After<br />Stopping</th><th id="hd_h_Ciprofloxacin.Tf_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a><br />(U/L)</th><th id="hd_h_Ciprofloxacin.Tf_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P<br />(U/L)</th><th id="hd_h_Ciprofloxacin.Tf_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a><br />(mg/dL)</th><th id="hd_h_Ciprofloxacin.Tf_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">18</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">8</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">388</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">..</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">..</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">INR 8.2. Admitted</td></tr><tr><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">20</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">10</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">723</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">114</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9.6</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">22</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">12</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1684</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">133</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">12.2</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Transferred</td></tr><tr><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">24</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">14</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1536</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">130</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">14.5</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">INR 2.1</td></tr><tr><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">26</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">16</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1406</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">136</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">18.2</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">28</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">18</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1157</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">122</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">21.1</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">INR 4.5</td></tr><tr><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">58</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">48</td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_3 hd_h_Ciprofloxacin.Tf_1_1_1_4 hd_h_Ciprofloxacin.Tf_1_1_1_5 hd_h_Ciprofloxacin.Tf_1_1_1_6" colspan="4" rowspan="1" style="text-align:center;vertical-align:top;">Patient died of multiorgan failure</td></tr><tr><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_1 hd_h_Ciprofloxacin.Tf_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;65</b></td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;135</b></td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Ciprofloxacin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Ciprofloxacin.Comment_1"><h4>Comment</h4><p>An example of acute hepatocellular injury attributed to ciprofloxacin. Metronidazole can also cause acute hepatocellular injury and acute liver failure, but such cases are exceedingly rare. In contrast, the precipitous onset and relatively short latency are typical of fluoroquinolone induced acute liver injury. Also, ciprofloxacin induced liver injury tends to be more common and more severe in the elderly.</p></div></div></div><div id="Ciprofloxacin.PRODUCT_INFORMATION"><h2 id="_Ciprofloxacin_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Ciprofloxacin &#x02013; Generic, Cipro&#x000ae;, Proquin&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antiinfective Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Ciprofloxacin" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Ciprofloxacin.CHEMICAL_FORMULA_AND_STRUC"><h2 id="_Ciprofloxacin_CHEMICAL_FORMULA_AND_STRUC_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Ciprofloxacin.Tg" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548066/table/Ciprofloxacin.Tg/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Ciprofloxacin.Tg_lrgtbl__"><table><thead><tr><th id="hd_h_Ciprofloxacin.Tg_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">DRUG</th><th id="hd_h_Ciprofloxacin.Tg_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CAS REGISTRY NO</th><th id="hd_h_Ciprofloxacin.Tg_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Ciprofloxacin.Tg_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Ciprofloxacin.Tg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ciprofloxacin HCl</td><td headers="hd_h_Ciprofloxacin.Tg_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135019641" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">86393-32-0</a></td><td headers="hd_h_Ciprofloxacin.Tg_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C17-H18-F-N3-O3.Cl-H.H2-O</td><td headers="hd_h_Ciprofloxacin.Tg_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135019641" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=135019641" alt="image 135019641 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="Ciprofloxacin.CITED_REFERENCES"><h2 id="_Ciprofloxacin_CITED_REFERENCES_">CITED REFERENCES</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="Ciprofloxacin.REF.1">Sherman O, Beizer JL. Possible ciprofloxacin-induced acute cholestatic jaundice. <span><span class="ref-journal">Ann Pharmacother. </span>1994;<span class="ref-vol">28</span>:1162–4.</span> [<a href="/pubmed/7841570" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7841570</span></a>]</div></dd><dt>2.</dt><dd><div class="bk_ref" id="Ciprofloxacin.REF.2">Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rochon J, Kleiner DE, Hayashi PH., DILIN Research Group.  Clinical and histopathologic features of fluoroquinolone-induced liver injury. <span><span class="ref-journal">Clin Gastroenterol Hepatol. </span>2011;<span class="ref-vol">9</span>:517–23.e3.</span> [<a href="/pmc/articles/PMC3718017/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3718017</span></a>] [<a href="/pubmed/21356330" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21356330</span></a>]</div></dd></dl></div><div id="Ciprofloxacin.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Ciprofloxacin_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 28 February 2020</p><p>Abbreviations used: SJS, Stevens Johnson syndrome; TEN, toxic epidermal necrolysis.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Ciprofloxacin.REF.zimmerman.1999">Zimmerman HJ. Quinolones. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999. p 603.<div><i>(Expert review of hepatotoxicity published in 1999 mentions that cinoxacin, nalidixic acid, ciprofloxacin, norfloxacin, enoxacin, and ofloxacin are associated with minor serum enzyme elevations during therapy and with rare instances of clinically apparent liver injury).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.moseley.2013">Moseley RH. Fluoroquinolones. Hepatotoxicity of antimicrobial and antifungal agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd Edition. Amsterdam: Elsevier, 2013. p. 468-9.<div><i>(Review of hepatotoxicity of antibiotics mentions that hepatocellular and cholestatic forms of injury have been reported due to the quinolones, including cases of ductopenia, acute liver failure and death).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.macdougall.2018">MacDougall C. The quinolones. Sulfonamides, trimethoprim-sulfamethoxazole, quinolones, and agents for urinary tract infections. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1015-8.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.halkin.1988.s258">Halkin H. Adverse effects of the fluoroquinolones. <span><span class="ref-journal">Rev Infect Dis. </span>1988;<span class="ref-vol">10</span> Suppl 1:S258–61.</span> [<a href="/pubmed/3279499" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3279499</span></a>]<div><i>(Combined analysis of databases provided by manufacturers on adverse events of fluoroquinolones in approximately 30,000 persons receiving ciprofloxacin, ofloxacin, pefloxacin, norfloxacin and enoxacin found similar types and rates of adverse events among the agents, overall in 4-8%, elevated liver enzymes in 1.8-2.5%, but eosinophilia in 2.4% with ciprofloxacin and 5-19% with ofloxacin).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.arcieri.1989.92s">Arcieri GM, Becker N, Esposito B, et al.  Safety of intravenous ciprofloxacin. A review. <span><span class="ref-journal">Am J Med. </span>1989;<span class="ref-vol">87</span> Suppl 5A:92S–97S.</span> [<a href="/pubmed/2686431" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2686431</span></a>]<div><i>(Summary on safety of intravenous ciprofloxacin based upon 1869 patients treated in 59 clinical trials; ALT elevations occurred in 2.0% and one patient had "hepatic necrosis").</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.kljucar.1989.52s">Kljucar S, Heimesaat M, von Pritzbuer E, Timm J, Scholl H, Beermann D. Efficacy and safety of higher-dose intravenous ciprofloxacin in severe hospital-acquired infections. <span><span class="ref-journal">Am J Med. </span>1989;<span class="ref-vol">87</span>:52S–56S.</span> [<a href="/pubmed/2589385" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2589385</span></a>]<div><i>(Elevated ALT levels occurred in 7 of 54 patients given high dose intravenous ciprofloxacin; no symptomatic hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.schacht.1989.98s">Schacht P, Arcieri G, Hullmann R. Safety of oral ciprofloxacin. An update based on clinical trial results. <span><span class="ref-journal">Am J Med. </span>1989;<span class="ref-vol">87</span> Suppl 5A:98S–102S.</span> [<a href="/pubmed/2686432" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2686432</span></a>]<div><i>(Industry report on 9473 courses of oral ciprofloxacin, usually given for 7-14 days: 9.3% had an adverse event, mostly mild, only 0.5% were serious. ALT elevations occurred in 1.3%, but jaundice in only 1 patient).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.slama.1990.904">Slama TG. Serum sickness-like illness associated with ciprofloxacin. <span><span class="ref-journal">Antimicrob Agents Chemother. </span>1990;<span class="ref-vol">34</span>:904–5.</span> [<a href="/pmc/articles/PMC171716/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC171716</span></a>] [<a href="/pubmed/2360826" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2360826</span></a>]<div><i>(56 year old man developed rash, fever, arthralgias and eosinophilia after 6 days of ciprofloxacin accompanied by mild enzyme elevations [bilirubin normal, ALT 102-307 U/L, Alk P 128-178 U/L], resolving rapidly with corticosteroid therapy).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.wolfson.1991.153s">Wolfson JS, Hooper DC. Overview of fluoroquinolone safety. <span><span class="ref-journal">Am J Med. </span>1991;<span class="ref-vol">91</span> Suppl 6A:153S–61S.</span> [<a href="/pubmed/1767803" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1767803</span></a>]<div><i>(Review of side effects reported in 22 clinical trials of fluoroquinolones; elevations in ALT and/or Alk P levels occurred in 1.8-2.7% of patients on cipro-, nor-, or ofloxacin).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.grassmick.1992.636">Grassmick BK, Lehr VT, Sundareson AS. Fulminant hepatic failure possibly related to ciprofloxacin. <span><span class="ref-journal">Ann Pharmacother. </span>1992;<span class="ref-vol">26</span>:636–9.</span> [<a href="/pubmed/1591420" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1591420</span></a>]<div><i>(66 year old man developed symptoms and jaundice after 1 day of starting ciprofloxacin [bilirubin 10.9 mg/dL, ALT 2608 U/L, Alk P 269 U/L] with shock, lactic acidosis and death 7 days later).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.jick.1993.461">Jick SS, Jick H, Dean AD. A follow-up safety study of ciprofloxacin users. <span><span class="ref-journal">Pharmacotherapy. </span>1993;<span class="ref-vol">13</span>:461–4.</span> [<a href="/pubmed/8247912" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8247912</span></a>]<div><i>(Follow up of ~37,000 patients for 45 days after receiving oral ciprofloxacin, none developed clinically apparent liver disease).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.levinson.1993.1619">Levinson JR, Kumar A. Ciprofloxacin induced cholestatic jaundice: a case report. <span><span class="ref-journal">Am J Gastroenterol. </span>1993;<span class="ref-vol">88</span>:1619.</span><div><i>(Abstract: 46 year old woman developed pruritus and jaundice within a few days of starting ciprofloxacin [bilirubin 10.6 mg/dL, ALT 519 U/L, Alk P 1459 U/L], resolving several weeks after stopping).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.fuchs.1994.738">Fuchs S, Simon Z, Brezin M. Fatal hepatic failure associated with ciprofloxacin. <span><span class="ref-journal">Lancet. </span>1994;<span class="ref-vol">343</span>:738–9.</span> [<a href="/pubmed/7907714" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7907714</span></a>]<div><i>(92 year old man developed "progressive hepatic failure" after 2 days of IV ciprofloxacin; no details given).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.sherman.1994.1162">Sherman O, Beizer JL. Possible ciprofloxacin-induced acute cholestatic jaundice. <span><span class="ref-journal">Ann Pharmacother. </span>1994;<span class="ref-vol">28</span>:1162–4.</span> [<a href="/pubmed/7841570" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7841570</span></a>]<div><i>(84 year old woman developed jaundice and rash after 7 days of ciprofloxacin therapy [bilirubin 8.2 mg/dL, ALT 126 U/L, Alk P 1119 U/L, resolving over ensuing 6 weeks: Case 1).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.ball.1995.343">Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Past, present and future. <span><span class="ref-journal">Drug Saf. </span>1995;<span class="ref-vol">13</span>:343–58.</span> [<a href="/pubmed/8652079" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8652079</span></a>]<div><i>(Review of the nature and frequency of adverse reactions to the fluoroquinolones mentions that clinically apparent liver injury is rare, but that severe and occasional fatal cases have been reported with ciprofloxacin, levofloxacin, norfloxacin and ofloxacin and from postmarketing surveillance has estimated the frequency of clinically apparent liver injury to be 0.8 per 100,000 recipients).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.aggarwal.1995.541">Aggarwal A, Gurka J. Probable ciprofloxacin induced cholestasis. <span><span class="ref-journal">Aust N Z J Med. </span>1995;<span class="ref-vol">25</span>:541–2.</span> [<a href="/pubmed/8588783" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8588783</span></a>]<div><i>(36 year old man developed marked Alk P elevations [peak 792 U/L] with minimal increases in ALT [61 U/L], without symptoms or jaundice within a week of starting ciprofloxacin, falling to baseline within 6 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.alcalde.1995.475">Alcalde M, Donoso MS, Carcfa-Diaz M, Pascasio JM, Narvaez I. Liver dysfunction due to ciprofloxacin. <span><span class="ref-journal">Acta Gastroenterol Belg. </span>1995;<span class="ref-vol">58</span>:475–6.</span> [<a href="/pubmed/8776005" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8776005</span></a>]<div><i>(27 year old man developed fatigue after 10 days of ciprofloxacin therapy [bilirubin 2.5 mg/dL, ALT 248 U/L, Alk P not available], resolving within 2 months of stopping).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.hautekeete.1995.759">Hautekeete ML, Kockx MM, Naegels S, Holvoet JK, Hubens H, Kloppel G. Cholestatic hepatitis related to quinolones: a report of two cases. <span><span class="ref-journal">J Hepatol. </span>1995;<span class="ref-vol">23</span>:759–60.</span> [<a href="/pubmed/8750178" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8750178</span></a>]<div><i>(50 year old man developed fatigue after 5 days of oral ciprofloxacin [bilirubin 4.8 rising to 9.3 mg/dL, ALT 202 U/L, Alk P 314 U/L], resolving within 9 weeks of stopping; second case due to ofloxacin).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.villeneuve.1995.257">Villeneuve JP, Davies C, C&#x000f4;t&#x000e9; J. Suspected ciprofloxacin-induced hepatotoxicity. <span><span class="ref-journal">Ann Pharmacother. </span>1995;<span class="ref-vol">29</span>:257–9.</span> [<a href="/pubmed/7606070" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7606070</span></a>]<div><i>(44 year old woman developed jaundice 2 weeks after finishing a 7 day course of ciprofloxacin [bilirubin 9.6 mg/dL, ALT 745 U/L, Alk P 284 U/L], with full recovery requiring 5 months).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.labowitz.1997.192">Labowitz JK, Silverman WB. Cholestatic jaundice induced by ciprofloxacin. <span><span class="ref-journal">Dig Dis Sci. </span>1997;<span class="ref-vol">42</span>:192–4.</span> [<a href="/pubmed/9009137" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9009137</span></a>]<div><i>(47 year old man developed jaundice and pruritus within 2 days of starting ciprofloxacin [bilirubin 10 rising to 34 mg/dL, ALT 308 U/L, Alk P 163 U/L], resolving slowly to normal over next 12 weeks).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.jones.1997.869">Jones SE, Smith RH. Quinolones may induce hepatitis. <span><span class="ref-journal">BMJ. </span>1997;<span class="ref-vol">314</span>(7084):869.</span> [<a href="/pmc/articles/PMC2126221/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2126221</span></a>] [<a href="/pubmed/9093098" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9093098</span></a>]<div><i>(21 year old man developed jaundice following a 5 day course of ofloxacin and two doses of ciprofloxacin [bilirubin 5.7 rising to 8.2 mg/dL, AST 348 U/L, Alk P 321 U/L], worsening for 7 days and then resolving within 5 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.contreras.2001.434">Contreras MA, Luna R, Mulero J, Andreu JL. Severe ciprofloxacin-induced acute hepatitis. <span><span class="ref-journal">Eur J Clin Microbiol Infect Dis. </span>2001;<span class="ref-vol">20</span>:434–5.</span> [<a href="/pubmed/11476450" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11476450</span></a>]<div><i>(32 year old man developed abdominal pain, fever and rash within 2 days of starting ciprofloxacin [bilirubin not given, ALT 147 rising to 2144 U/L, GGT 98 U/L], with subsequent signs of liver failure, but ultimate recovery after methylprednisolone therapy).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.morelli.2001.2385">Morelli MS, O'Brien FX. Stevens-Johnson Syndrome and cholestatic hepatitis. <span><span class="ref-journal">Dig Dis Sci. </span>2001;<span class="ref-vol">46</span>:2385–8.</span> [<a href="/pubmed/11713940" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11713940</span></a>]<div><i>(19 year old woman developed fever followed by rash and jaundice 4 days after starting ibuprofen and 2 days after starting metoclopramide and ketorolac [bilirubin 3.3 rising to 9.2 mg/dL, ALT 300 U/L, Alk P 409 U/L], with worsening fever and rash diagnosed as Stevens Johnson syndrome [SJS], resolving without corticosteroid therapy).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.bataille.2002.696">Bataille L, Rahier J, Geubel A. Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn's disease. <span><span class="ref-journal">J Hepatol. </span>2002;<span class="ref-vol">37</span>:696–9.</span> [<a href="/pubmed/12399240" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12399240</span></a>]<div><i>(63 year old woman with Crohn disease developed jaundice while being treated with ciprofloxacin and ornidazole [a nitroimidazole derivative also linked to cases of cholestatic jaundice] for 6 months [bilirubin 3.4 rising to 8.1 mg/dL, ALT 740 U/L, Alk P 662 U/L], liver biopsy showing paucity of bile ducts, slowly resolving over the 8 months after discontinuation of both drugs).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.h_llgren.2003.s267">H&#x000e4;llgren J, Tengvall-Linder M, Persson M, Wahlgren CF. Stevens-Johnson syndrome associated with ciprofloxacin: a review of adverse cutaneous events reported in Sweden as associated with this drug. <span><span class="ref-journal">J Am Acad Dermatol. </span>2003;<span class="ref-vol">49</span>(5) Suppl:S267–9.</span> [<a href="/pubmed/14576649" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14576649</span></a>]<div><i>(31 and 33 year old women developed rash and oral ulcers diagnosed as SJS 2 and 8 days after starting ciprofloxacin [one with serum enzyme elevations without jaundice], and review of Swedish Drug Information System found 8 other cases of serious cutaneous reactions due to ciprofloxacin).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.goetz.2003.294">Goetz M, Galle PR, Schwarting A. Non-fatal acute liver injury possibly related to high-dose ciprofloxacin. <span><span class="ref-journal">Eur J Clin Microbiol Infect Dis. </span>2003;<span class="ref-vol">22</span>:294–6.</span> [<a href="/pubmed/12739107" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12739107</span></a>]<div><i>(79 year old woman developed confusion and lactic acidosis within 2 days of starting iv ciprofloxacin [peak bilirubin 1.6 mg/dL, ALT 4878 U/L, Alk P 581 U/L, LDH 6111 U/L], resolving within 2 weeks).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.zaidi.2003.31">Zaidi SA. Hepatitis associated with amoxicillin/clavulanic acid and/or ciprofloxacin. <span><span class="ref-journal">Am J Med Sci. </span>2003;<span class="ref-vol">325</span>:31–3.</span> [<a href="/pubmed/12544082" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12544082</span></a>]<div><i>(80 year old man received both ciprofloxacin and amoxicillin/clavulanate, developing rash and eosinophilia within 1 week followed by self-limiting serum enzyme elevations without jaundice [bilirubin 1.9 mg/dL, ALT 972 U/L, Alk P 358 U/L]).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.zimpfer.2004.87">Zimpfer A, Propst A, Mikuz G, Vogel W, Terracciano L, Stadlmann S. Ciprofloxacin-induced acute liver injury: case report and review of literature. <span><span class="ref-journal">Virchows Arch. </span>2004;<span class="ref-vol">444</span>:87–9.</span> [<a href="/pubmed/14994731" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14994731</span></a>]<div><i>(22 year old man developed jaundice 1 week after finishing a 7 day course of ciprofloxacin [bilirubin 16.9 mg/dL, ALT 890 U/L, Alk P 180 U/L], symptoms and liver test abnormalities resolving within a week of starting methylprednisolone).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.thakur.2007.51">Thakur BS, Jain AK, Sirkar S, Joshi G, Joshi R. Ciprofloxacin-induced cholestatic jaundice. <span><span class="ref-journal">Indian J Gastroenterol. </span>2007;<span class="ref-vol">26</span>(1):51–2.</span> [<a href="/pubmed/17401251" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17401251</span></a>]<div><i>(26 year old man developed rash and then jaundice within 5 days of starting ciprofloxacin [ALT 1700 U/L], with slow recovery by 6 months after onset).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.bhagirath.2008.204">Bhagirath KM. A case report of highly suspected ciprofloxacin-induced hepatotoxicity. <span><span class="ref-journal">Turk J Gastroenterol. </span>2008;<span class="ref-vol">19</span>:204–6.</span> [<a href="/pubmed/19115163" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19115163</span></a>]<div><i>(39 year old woman developed jaundice 1 month after a 14 day course of ciprofloxacin and metronidazole [bilirubin 16.3 mg/dL, ALT 1406 U/L, Alk P 160 U/L, IRN 1.6], resolving within the next 3 months with prednisone therapy).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.dichiara.2008.307">Dichiara AJ, Atkinson M, Goodman Z, Sherman KE. Ciprofloxacin-induced acute cholestatic liver injury and associated renal failure. Case report and review. <span><span class="ref-journal">Minerva Gastroenterol Dietol. </span>2008;<span class="ref-vol">54</span>:307–15.</span> [<a href="/pubmed/18614979" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18614979</span></a>]<div><i>(65 year old man developed jaundice 6 days into a course of ciprofloxacin for cellulitis [bilirubin 8.5 rising to 25 mg/dL, ALT 157 U/L, Alk P 711 U/L], with concurrent renal failure, and slow but eventual recovery 5 months later).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.chalasani.2008.1924">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J., Drug Induced Liver Injury Network (DILIN).  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, the fluoroquinolones accounting for 10 cases [3%], including 5 attributed to ciprofloxacin [ranking 8th], 4 to levofloxacin, and 1 to moxifloxacin).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.okan.2008.4697">Okan G, Yaylaci S, Peker O, Kaymakoglu S, Saruc M. Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus. <span><span class="ref-journal">World J Gastroenterol. </span>2008;<span class="ref-vol">14</span>:4697–700.</span> [<a href="/pmc/articles/PMC2738797/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2738797</span></a>] [<a href="/pubmed/18698687" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18698687</span></a>]<div><i>(26 year old woman developed fever and rash 2 weeks after starting ciprofloxacin [bilirubin 4.1 rising to 34 mg/dL, ALT 326 U/L, Alk P 229 U/L], biopsies showing SJS and bile duct loss, and ultimately improving and recovery with ursodiol, prednisone and tacrolimus therapy).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.miftode.2008.652">Miftode E, Leca D, Luca V. <span><span class="ref-journal">Rev Med Chir Soc Med Nat Iasi. </span>2008;<span class="ref-vol">112</span>:652–5.</span> [A severe case of infectious mononucleosis associated with ciprofloxacin and salazopyrin administration] Romanian. [<a href="/pubmed/20201247" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20201247</span></a>]<div><i>(22 year old woman developed rash and severe hepatitis 32 days after starting sulfasalazine and 2 days after ciprofloxacin [bilirubin 36 mg/dL, ALT 488 U/L]).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.cholongitas.2009.400">Cholongitas E, Georgousaki C, Spyrou S, Dasenaki M. Ciprofloxacin-induced acute cholestatic hepatitis. <span><span class="ref-journal">Ann Hepatol. </span>2009;<span class="ref-vol">8</span>:400–1.</span> [<a href="/pubmed/20009146" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20009146</span></a>]<div><i>(66 year old man developed liver enzyme elevations 3 days after starting intravenous ciprofloxacin [direct bilirubin 1.9, ALT 582 U/L, Alk P 1234 U/L], with worsening for 7 days and then resolving within 3 months of stopping).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.reuben.2010.2065">Reuben A, Koch DG, Lee WM., Acute Liver Failure Study Group.  Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, of which 1 was attributed to ciprofloxacin, but none to other fluoroquinolones).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.alan.2011.189">Alan C, Ko&#x000e7;o&#x0011f;lu H, Ersay AR, Ertung Y, Kurt HA. Unexpected severe hepatotoxicity of ciprofloxacine: two case reports. <span><span class="ref-journal">Drug Chem Toxicol. </span>2011;<span class="ref-vol">34</span>(2):189–91.</span> [<a href="/pubmed/21314468" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21314468</span></a>]<div><i>(Two cases; 56 and 62 year old men developed liver injury 2 and 5 days after starting ciprofloxacin [bilirubin ~5.0 mg/dL, ALT 500 and 320 U/L, Alk P 152 and 132 U/L, prothrombin time 57 and 34 secs], both recovering rapidly upon stopping).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.orman.2011.517">Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rochon J, Kleiner DE, Hayashi PH., DILIN Research Group.  Clinical and histopathologic features of fluoroquinolone-induced liver injury. <span><span class="ref-journal">Clin Gastroenterol Hepatol. </span>2011;<span class="ref-vol">9</span>:517–23.e3.</span> [<a href="/pmc/articles/PMC3718017/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3718017</span></a>] [<a href="/pubmed/21356330" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21356330</span></a>]<div><i>(Among 679 cases of drug induced liver injury presenting between 2004 and 2010 at 8 US medical centers, 12 [1.8%] were attributed to fluoroquinolones including 6 cipro-, 4 moxi-, 1 levo-, and 1 gatifloxacin; average time to onset was 4 days [range 1-39], with both hepatocellular and cholestatic enzyme patterns, 7 with rash or fever, mortality limited to those with hepatocellular injury and jaundice; the pattern of hepatic injury appeared to be shared among the fluoroquinolones: Case 2).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.paterson.2012.1565">Paterson JM, Mamdani MM, Manno M, Juurlink DN., Canadian Drug Safety and Effectiveness Research Network.  Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. <span><span class="ref-journal">CMAJ. </span>2012;<span class="ref-vol">184</span>:1565–70.</span> [<a href="/pmc/articles/PMC3470619/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3470619</span></a>] [<a href="/pubmed/22891208" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22891208</span></a>]<div><i>(In a population based study using Canadian health care databases, the risk of admission to hospital for acute liver injury was increased for persons who received a prescription for moxifloxacin or levofloxacin relative to clarithromycin, but not for ciprofloxacin).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.hayashi.2012.1555">Hayashi PH, Chalasani NP. Liver injury in the elderly due to fluoroquinolones: should these drugs be avoided? <span><span class="ref-journal">CMAJ. </span>2012;<span class="ref-vol">184</span>:1555–6.</span> [<a href="/pmc/articles/PMC3470615/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3470615</span></a>] [<a href="/pubmed/22891207" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22891207</span></a>]<div><i>(Editorial in response to Paterson [2013] stressing the low absolute risk of liver injury from the fluoroquinolones [4-9 per 100,000 exposures]).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.kwon.2012.268">Kwon H, Lee SH, Kim SE, Lee JH, Jee YK, Kang HR, Park BJ, et al.  Spontaneously reported hepatic adverse drug events in Korea: multicenter study. <span><span class="ref-journal">J Korean Med Sci. </span>2012;<span class="ref-vol">27</span>:268–73.</span> [<a href="/pmc/articles/PMC3286773/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3286773</span></a>] [<a href="/pubmed/22379337" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22379337</span></a>]<div><i>(Summary of 2 years of adverse event reporting in Korea; of 9360 reports, 567 were liver related, including 29 [5.1%] attributed to quinolones).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.harr.2012.149">Harr T, French LE. Stevens-Johnson syndrome and toxic epidermal necrolysis. <span><span class="ref-journal">Chem Immunol Allergy. </span>2012;<span class="ref-vol">97</span>:149–66.</span> [<a href="/pubmed/22613860" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22613860</span></a>]<div><i>(Review of the clinical features, epidemiology, genetics and pathogenesis of SJS and TEN).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.patel.2013.389">Patel TK, Barvaliya MJ, Sharma D, Tripathi C. A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population. <span><span class="ref-journal">Indian J Dermatol Venereol Leprol. </span>2013;<span class="ref-vol">79</span>:389–98.</span> [<a href="/pubmed/23619444" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23619444</span></a>]<div><i>(Systematic review of 10 case series of SJS/TEN from India identified 352 cases, among which 342 implicated a medication with most common being antimicrobials [37%], anticonvulsants [16%] and NSAIDs [16%]; fluoroquinolones accounted for 33 cases [10%], 4 of which were due to ciprofloxacin, 1 ofloxacin and 1 levofloxacin).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.bj_rnsson.2013.1419">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. <span><span class="ref-journal">Gastroenterology. </span>2013;<span class="ref-vol">144</span>:1419–25.</span> [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, none of which were attributed to ciprofloxacin or other fluoroquinolones).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.hern_ndez.2014.231">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A, Chirino R, et al.  Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:231–9.</span> [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, one due to trovafloxacin [acute liver failure], but none attributed to ciprofloxacin or other fluoroquinolones).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.alshammari.2014.37">Alshammari TM, Larrat EP, Morrill HJ, Caffrey AR, Quilliam BJ, LaPlante KL. Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study. <span><span class="ref-journal">Am J Health Syst Pharm. </span>2014;<span class="ref-vol">71</span>:37–43.</span> [<a href="/pubmed/24352180" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24352180</span></a>]<div><i>(Retrospective analysis of Veterans Affairs patients receiving a fluoroquinolone [n=7862] found a higher relative risk of developing acute liver injury after receipt of ciprofloxacin compared to matched controls [adjusted odds ratio: OR=1.29], but not after receipt of levofloxacin [OR=1.16) or moxifloxacin [OR=0.98]).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.goldberg.2015.1353">Goldberg DS, Forde KA, Carbonari DM, Lewis JD, Leidl KB, Reddy KR, Haynes K, et al.  Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1353–61.e3.</span> [<a href="/pmc/articles/PMC4446162/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446162</span></a>] [<a href="/pubmed/25733099" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25733099</span></a>]<div><i>(Analysis of Kaiser Permanente health care database from 2004 to 2011 identified 62 patients with suspected acute liver failure, 32 [52%] of whom had a presumed drug etiology, the most common being acetaminophen [18: 56%] and various herbal products [5: 16%], with single instances attributed to imatinib, simvastatin, leflunomide, isoniazid and valproate, but none to ciprofloxacin or other fluoroquinolones).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 38 cases [4%] were attributed to fluoroquinolones, including 16 due to ciprofloxacin [the 8th most common prescription drug cause], 13 due to levofloxacin and 8 to moxifloxacin).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.moreno.2015.767">Moreno L, S&#x000e1;nchez-Delgado J, Vergara M, Casas M, Miquel M, Dalmau B. Recurrent drug-induced liver injury (DILI) with ciprofloxacin and amoxicillin/clavulanic. <span><span class="ref-journal">Rev Esp Enferm Dig. </span>2015;<span class="ref-vol">107</span>:767–8.</span> [<a href="/pubmed/26671593" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26671593</span></a>]<div><i>(56 year old woman developed pruritus and dark urine 4 and jaundice 10 days after starting ciprofloxacin [bilirubin 9.5 mg, ALT 506 U/L, Alk P 455 U/L, eosinophils 10%, INR 0.98] and, after recovery, developed jaundice again 9 days after starting amoxicillin/clavulanate [bilirubin 8.5 mg/dL, ALT 692 U/L, Alk P 348 U/L, eosinophils 3%], no information on recovery).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.kaddumulindwa.2016.1173">Kaddu-Mulindwa D, Lammert F, Ma&#x000df;mann A, Link A. <span><span class="ref-journal">Dtsch Med Wochenschr. </span>2016;<span class="ref-vol">141</span>:1173–6.</span> [Acute liver failure after ingestion of ciprofloxacin] [<a href="/pubmed/27509349" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27509349</span></a>]<div><i>(23 year old woman developed nausea 1 day and jaundice 5 days after starting ciprofloxacin [bilirubin 10.8 mg/dL, ALT 3431 U/L, Alk P 152 U/L, INR 2.5], with severe but self-limiting course, resolving completely over the next 6 months).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.goldie.2016.bcr2016216048">Goldie FC, Brogan A, Boyle JG. Ciprofloxacin and statin interaction: a cautionary tale of rhabdomyolysis. <span><span class="ref-journal">BMJ Case Rep. </span>2016;<span class="ref-vol">2016</span>:bcr2016216048. </span> pii. [<a href="/pmc/articles/PMC4986139/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4986139</span></a>] [<a href="/pubmed/27469384" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27469384</span></a>]<div><i>(62 year old woman on long term simvastatin developed rhabdomyolysis 4 days after starting ciprofloxacin [bilirubin and Alk P not given, ALT 240 U/L, CPK 24524 U/L], resolving with stopping both drugs, ALT elevations likely due to muscle rather than liver injury).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.bonkovsky.2017.1267">Bonkovsky HL, Kleiner DE, Gu J, Odin JA, Russo MW, Navarro VM, Fontana RJ, Ghabril MS, et al. U.S. Drug Induced Liver Injury Network Investigators.  Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. <span><span class="ref-journal">Hepatology. </span>2017;<span class="ref-vol">65</span>:1267–77.</span> [<a href="/pmc/articles/PMC5360519/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5360519</span></a>] [<a href="/pubmed/27981596" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27981596</span></a>]<div><i>(Among 363 patients with drug induced liver injury who underwent liver biopsy, 26 [7%] had bile duct loss of whom 94% developed evidence of chronic liver injury suggestive of vanishing bile duct syndrome, 2 of which were due to fluoroquinolones, 1 moxifloxacin and 1 levofloxacin).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF55">Comparison table: some systemic fluoroquinolones. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2018;<span class="ref-vol">60</span>:e57–e58.</span> [<a href="/pubmed/29635268" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29635268</span></a>]<div><i>(Table comparing 4 fluoroquinolones [cipro-, levo-, dela- and moxifloxacin] mentions that ALT and AST elevations are a class adverse event).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.mavros.2019.746">Mavros MN, Theochari NA, Kyriakidou M, Economopoulos KP, Sava JA, Falagas ME. Fluoroquinolone-based versus &#x003b2;-lactam-based regimens for complicated intra-abdominal infections: a meta-analysis of randomised controlled trials. <span><span class="ref-journal">Int J Antimicrob Agents. </span>2019;<span class="ref-vol">53</span>:746–54.</span> [<a href="/pubmed/30639629" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30639629</span></a>]<div><i>(Systematic review of controlled trials of fluoroquinolones versus &#x003b2;-lactam-based antibiotic regimens found similar rates of efficacy and adverse events, no discussion of ALT elevations or liver related toxicities).</i></div></div></li><li><div class="bk_ref" id="Ciprofloxacin.REF.kuula.2019.e0216029">Kuula LSM, Viljemaa KM, Backman JT, Blom M. Fluoroquinolone-related adverse events resulting in health service use and costs: A systematic review. <span><span class="ref-journal">PLoS One. </span>2019;<span class="ref-vol">14</span>:e0216029. </span> [<a href="/pmc/articles/PMC6485715/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6485715</span></a>] [<a href="/pubmed/31026286" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31026286</span></a>]<div><i>(Systematic review of observational studies on safety of fluoroquinolones concluded that due to lack of published literature, health service and costs could not be evaluated).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548066</span><span class="label">PMID: <a href="/pubmed/31643397" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643397</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Cimetidine/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Cisplatin/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548066&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548066/?report=reader">PubReader</a></li><li><a href="/books/NBK548066/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548066" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548066" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Ciprofloxacin. [Updated 2020 Feb 28].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548066/pdf/Bookshelf_NBK548066.pdf">PDF version of this page</a> (166K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=ciprofloxacin/AE+AND+Human%5BMH%5D+AND+(jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI+OR+hepatitis,+toxic%5BMH%5D)+AND+(%222008/07%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Ciprofloxacin: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=ciprofloxacin" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Ciprofloxacin: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4855832" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4855832" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4855832" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643678" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Levofloxacin</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Levofloxacin<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31644097" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gemifloxacin</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gemifloxacin<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/8736621" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.</a><span class="source">[Drugs. 1996]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Davis R, Markham A, Balfour JA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drugs. 1996 Jun; 51(6):1019-74. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/11581056" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.</a><span class="source">[Ophthalmology. 2001]</span><div class="brieflinkpop offscreen_noflow">An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kowalski RP, Pandya AN, Karenchak LM, Romanowski EG, Husted RC, Ritterband DC, Shah MK, Gordon YJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ophthalmology. 2001 Oct; 108(10):1826-9. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/3311572" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ciprofloxacin and norfloxacin, two fluoroquinolone antimicrobials.</a><span class="source">[Clin Pharm. 1987]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ciprofloxacin and norfloxacin, two fluoroquinolone antimicrobials.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nix DE, DeVito JM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Pharm. 1987 Feb; 6(2):105-17. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643397" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643397" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60467c864664552c12780554">Ciprofloxacin - LiverTox</a><div class="ralinkpop offscreen_noflow">Ciprofloxacin - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:35:34-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal106&amp;ncbi_phid=CE8D161D04663E5100000000058F01A1&amp;ncbi_session=CE8D161D0467C851_1423SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548066%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548066&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548066/&amp;ncbi_pagename=Ciprofloxacin - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D161D0467C851_1423SID /projects/books/PBooks@9.2 portal106 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>